calcipotriene

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
calcipotriene
Generic name
CALCIPOTRIENE
Manufacturer
Glenmark Pharmaceuticals Inc.,USA
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
7ec750f6-26ea-46bc-aa7b-174fd25253a2
SPL ID
2feacaaa-677d-4ab6-878e-4e909f57488d
Version
8
Effective date
2026-10-07
Source export date
2026-11-13
Source partition
14
Source file
https://download.open.fda.gov/drug/label/drug-label-0014-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/087e7a9c7af51c6b12a0e8fd611a27cb8635e1910ad160b89995da9a4b39b1b3/drug-label-0014-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 18:17:57
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Contact dermatitis, including allergic contact dermatitis, has been observed with the use of calcipotriene cream.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS Clinical Trials Experience In controlled clinical trials, the most frequent adverse experiences reported for calcipotriene cream, 0.005% were cases of skin irritation, which occurred in approximately 10 to 15% of patients. Rash, pruritus, dermatitis and worsening of psoriasis were reported in 1 to 10% of patients. Postmarketing Experience The following adverse reactions have been identified during postapproval use of calcipotriene Cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Metabolism and nutrition disorders: hypercalcemia Renal and urinary disorders: hypercalciuria Skin and subcutaneous tissue disorder: application site edema, application site pain, contact dermatitis (including allergic contact dermatitis), depigmentation, dry skin, erythema, hyperpigmentation, hypopigmentation, photosensitivity, rash (including erythematous, maculo-papular, and pustular), skin burning sensation, skin exfoliation, and urticaria. To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.